1. Quality of life in patients with advanced epithelial ovarian cancer (EOC) randomized to maintenance pazopanib or placebo after first-line chemotherapy in the AGO-OVAR 16 trial. Measuring what matters—patient-centered end points in trials of maintenance therapy. (18th December 2017) Authors: Friedlander, M; Rau, J; Lee, C K; Meier, W; Lesoin, A; Kim, J -W; Poveda, A; Buck, M; Scambia, G; Shimada, M; Hilpert, F; King, M T; Debruyne, P; Bologna, A; Malander, S; Monk, B J; Petru, E; Calvert, P; Herzog, T J; Barrett, C Journal: Annals of oncology Issue: Volume 29:Number 3(2018) Page Start: 737 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗